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weeks of treatment. An exponential reduction of CFU counts
was observed. Although two patients developed severe
hypokalemia, glomerular renal function was well preserved
in all patients with creatinine serum levels below 1.5mg/dl
at end of 14 days of antifungal therapy.
Conclusion: Continuous infusion of amphotericin B seems
to be safe and well tolerated. Mycological efﬁcacy was com-
parable as standard of treatment, with adequate reduction
rate of CFU and sterilization of CSF. These data could suggest
that continuous infusion reduces nephrotoxicity while keep-
ing fungicidal activity. Larger and comparative trials, against
new lipid formulations and even novel antifungal agents, are
necessary to further evaluate this treatment regimen.
doi:10.1016/j.ijid.2008.05.759
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Introduction: The incidence of invasive fungal infections
is increasing worldwide and rare fungi - neither belonging to
the genera Aspergillus, Candida, Pneumocystis or Crypto-
coccus, nor being endemic or regional, such as Histoplasma
spp. or Coccidioides spp. - are increasingly identiﬁed as
causative pathogens. Reliable, evidence based treatment
recommendations for these species have not been estab-
lished, yet.
Methods: We are coordinating a global registry for cases
of rare invasive fungi. Our objective is to broaden the knowl-
edge on epidemiology, to determine the clinical pattern
of disease, to describe and improve diagnostic proce-
dures and therapeutic regimens, as well as to to facilitate
exchange of clinical isolates among the contributors. Entry
of retrospective data occurs via a web-based registration
system (MACRO) that focuses on demographic information,
underlying diseases, risk factors, details on the infection
(pathogen, localization, specimen collection) therapy and
outcome. Inclusion criteria include cultural, histopatholog-
ical, antigen, or DNA evidence of invasive fungal infection.
Infection due to Aspergillus spp., Candida spp., Crypto-
coccus neoformans, Pneumocystis jiroveci or any endemic
fungal infection, such as coccidioidomycosis or histoplasmo-
sis, as well as colonisation or other non-invasive infection
are exclusion criteria.
Results: By now, 28 cases of rare mycoses have been
identiﬁed, including Absidia corymbifera, Cunninghamella
bertholletiae, Penicillium marneffei, Rhizomucor pusillus,
as well as Acremonium spp., Fusarium spp., Coccidioides
spp., and Trichoderma spp. Clinical results are partly pend-
ing. Most patients were in an immunocompromised state as
a result of their underlying disease, chemotherapy or trans-
plantation.
Discussion: The clinical relevance of invasive fungal
infections by rare fungi is increasing steadily. In a short
period of time, actual cases from Germany, Austria, Italy
and the United Kingdom could be documented, showing
the broad spectrum of pathogens. Further investigators and
coordinators are cordially invited to contribute to the suc-
cess of Fungiscope!
doi:10.1016/j.ijid.2008.05.760
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Aspergillus fumigatus is an opportunistic and one of the
most ubiquitous of the airborne saprophytic fungi which
causes a number of life threatening diseases in humans
and animals. Invasive aspergillosis which occurs in a wide
range of clinical scenarios is protean in its manifestations,
and is still associated with an unacceptably high mor-
tality rate. People most at risk for aspergillosis include
patients with advanced AIDS, prolonged neutropenia, allo-
geneic hematopoietic stem cell transplant recipients, solid
organ transplant recipients, and chronic granulomatous dis-
ease. The difﬁculties of early diagnosis and treatment of
fungal infections has given rise to high mortality rate.
Indeed, these infections are all too frequently diagnosed
at an advanced stage and prone to rapid progression. In
fact, the vital signiﬁcance of early and accurate diagnosis
of Aspergillus infections and the substantiated pathogenic
has been the main reason behind the current study. In this
regard the production and partial characterization of eleven
monoclonal antibodies (MAbs) directed against the cell wall
antigens of Aspergillus fumigatus in immunized BALB/c mice
is described. Three IgM and eight IgG monoclonal antibod-
ies were produced. Two IgG MAbs were chosen to large
scale production and puriﬁcation. They did not show any
cross-reactivity with other pathogenic species of Aspergillus
and Candida. The above antibodies displayed a substantial
amount of sensitivity and speciﬁcity. Also, they proved to
be effective in detecting Aspergillus fumigatus antigens in
lung and kidney tissues of mice infected with Aspergillus
fumigatus.
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